Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Gears Up For Compulsory Licensing Reform

Executive Summary

The European Commission has laid out a number of possibilities for changing the EU framework on compulsory licensing to improve the availability of products in health emergencies. The options include extending the scope of compulsory licences beyond patents to other forms of protection such as data exclusivity.

You may also be interested in...



EU Explains Plans For Use Of ‘Last Resort’ Compulsory Licensing

The first stage of the EU’s proposal to revamp the compulsory licensing system and prepare the bloc for future health crises is almost complete. The next steps are to publish an impact assessment, run a public consultation, and produce a draft regulation by the first quarter of 2023.

WHO To Review Impact Of Mechanism For Tackling Substandard & Falsified Drugs

Recent incidents of illness and death caused by contaminated cough syrups show that there is a need to review the “member state mechanism” that is intended to coordinate efforts to tackle poor quality medical products, the World Health Organization says.

International Regulators Focus On Omicron XBB For Monovalent COVID-19 Vaccine

A workshop led by the European Medicines Agency and the US Food and Drug Administration sought to reach alignment on adapting COVID-19 vaccines to emerging virus variants.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152166

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel